TargetMol

Rosiglitazone

Product Code:
 
TAR-T0334
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0334-25mg25mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0334-50mg50mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0334-1mL1 mL * 10 mM (in DMSO)£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0334-100mg100mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0334-200mg200mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.
CAS:
122320-73-4
Formula:
C18H19N3O3S
Molecular Weight:
357.43
Pathway:
Membrane transporter/Ion channel; Metabolism; DNA Damage/DNA Repair; Apoptosis; Autophagy; Cell Cycle/Checkpoint
Purity:
0.9987
SMILES:
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Target:
Ferroptosis; TRP/TRPV Channel; PPAR; Autophagy

References

1. Fryer LG, et al. J Biol Chem, 2002, 277(28), 25226-25232. 2. Rzonca SO, et al. Endocrinology, 2004, 45(1), 401-406. 3. Motoshima H, et al. J Clin Endocrinol Metab, 2002, 87(12), 5662-5667. 4. Wilson-Fritch L, et al. J Clin Invest, 2004, 114(9), 1281-1289. 6. Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220. 7. Qiu Y, Sun Y, Xu D, et al. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue[J]. EBioMedicine. 2018, 37: 344-355. 8. Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks[J]. Chemical Science. 2020, 11(7): 1775-1797.